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ABSTRACT: The aim of this study was to evaluate whether the cold-water extracts of Pleurotus eryngii var. ferulae 
(CWE-Pef) and Pleurotus nebrodensis (CWE-Pn), 2 of the most prized wild and cultivated edible mushrooms, can 
affect the tumor phenotype of human colon cancer HCT116 cells. Our results showed that treatment with CWE-
Pef and CWE-Pn resulted in a significant inhibition of the viability of HCT116 cells and promoted apoptosis, as 
also demonstrated by the increase of Bax-to-Bcl-2 messenger RNA ratio. Moreover, we observed that both extracts 
were able to inhibit cell migration and to affect homotypic and heterotypic cell-cell adhesion. It also was found that 
treatment with CWE-Pef and CWE-Pn negatively modulated the phosphorylation of the protein tyrosine as well as 
the phosphorylation levels of extracellular signal-regulated kinase 1/2. In conclusion, the in vitro antitumor effects of 
CWE-Pef and CWE-Pn indicate that they can be considered as possible sources for new alternative therapeutic agents 
for cancer treatment. 
KEY WORDS: medicinal mushrooms, Pleurotus eryngii var. ferulae, Pleurotus nebrodensis, human colon cancer, 
antitumor activity
ABBREVIATIONS: CWE-Pef, cold-water extract from Pleurotus eryngii var. ferulae; CWE-Pn, cold-water extract 
from Pleurotus nebrodensis; DMSO, dimethyl sulfoxide; HUVEC, human umbilical cord endothelial cell; mRNA, 
messenger RNA; PCR, polymerase chain reaction. 
I. INTRODUCTION
Colorectal cancer is the third most commonly diag-
nosed cancer in males and the second in females. 
Almost 50% of patients diagnosed with colorectal 
cancer die because of the disease and only less than 
10% of patients with metastatic cancer survive more 
than 5 years after their diagnosis.1 Although some 
patients with early-stage colon cancer can be cured 
by surgical resection alone, usually the treatment 
of both early and advanced colorectal cancers is 
based on a multimodal approach in which surgery is 
combined with adjuvant radio- and chemotherapy.2 
However, the severe side effects of these therapies 
too often supersede their benefits and worsen pa-
tients’ quality of life. For this reason, the discovery 
of new, safer, and more effective therapeutic agents 
is needed to better treat colon cancer. 
Mushrooms have been used for centuries as 
folk medicines, especially in Asian countries, where 
their medicinal properties are well known. Because 
of the great quantity of experimental evidence col-
lected in the past two decades, the immunomodu-
latory and antineoplastic properties of substances 
extracted from various species of edible mushrooms 
are now also extensively recognized at a scientif-
ic level.3 The most promising biologically active 
compounds obtained from mushrooms are polysac-
charides,4–7 polysaccharide-protein complexes,8,9 
proteins,10–12 and triterpenes.13–15 Several published 
works have demonstrated that the anticancer proper-
ties of these molecules is due to their ability to en-
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hance immune system activity and/or act directly 
on cancer cells.3–5,9,11,15,16 Some of the most studied 
medicinal mushrooms are those belonging to the 
genus Pleurotus (Fr.) P. Kumm., which includes 
widely cultivated edible mushrooms.3,17 Most of 
the research concerning the antitumor properties of 
Pleurotus spp. have been carried out by testing the 
methanol/ethanol/hot water extracts of P. ostreatus 
(Jacq.:Fr.) P. Kumm. in several in vivo and in vitro 
cancer models.3,17–23 These studies have provided 
interesting data supporting the possibility of isolat-
ing new therapeutic agents from this mushroom, 
but much less is known about the biological activi-
ties of extracts from other Pleurotus species. 
Pleurotus eryngii (DC.:Fr.) Quél. var. ferulae 
(Lanzi) Sacc. and P. nebrodensis (Inzenga) Quél. are 
typical Mediterranean mushroom species and are 
particularly popular as choice edible mushrooms. 
P. eryngii var. ferulae is abundantly collected from 
calcareous soils in garigues, wastelands, and arid 
pastures from September to mid-June, from sea 
level to an elevation of approximately 1000 m. P. 
nebrodensis is a rare and declining mushroom with 
a fructification period restricted from mid-April to 
mid-June. It grows in arid pastures in calcareous 
soils at elevations of 1200 to 2000 m.24
Isozyme and random amplification of poly-
morphic DNA polymerase chain reaction (PCR) 
analyses have confirmed that P. eryngii var. fer-
ulae and P. nebrodensis are clearly genetically 
different.25 As reported by La Guardia et al.26 the 
wild and cultivated P. eryngii var. ferulae and P. 
nebrodensis mushrooms are suitable in every type 
of diet, including hypocaloric diets, thanks to their 
low caloric content and gastronomic value. In ad-
dition, these mushrooms are a good source of vita-
mins and mineral salts.
The aim of this study was to evaluate whether 
the cold-water extracts of P. eryngii var. ferulae 
(CWE-Pef) and P. nebrodensis (CWE-Pn) can af-
fect the tumor phenotype of human colon cancer 
cells. We found that CWE-Pef and CWE-Pn inhib-
ited the growth of HCT116 colon cancer cells by 
inducing apoptosis, promoted cancer cell aggrega-
tion, and inhibited cell migration and the adhesion 
of tumor cells to endothelial cells. These effects 
were specific for tumor cells; no effects were ob-
served on nontumor cells. 
II. MATERIALS AND METHODS
A. Mushroom Extracts
The mushroom samples were cleaned of debris 
with a knife, cut into pieces and placed in plastic 
bags for freezing, then transported to a laboratory 
and frozen at -80°C. Every sample contained com-
plete mushroom basidiomata (cap, gills, and stipe). 
The mushrooms were identified according to mac-
ro- and micromorphological descriptions reported 
by previous studies.24,27 The original material of 
mushroom basidiomata is kept in the Laboratory 
of Mycology at the Department of Agricultural and 
Forest Science, University of Palermo.
Finally, the frozen mushrooms were lyophi-
lized. According to internal quality control proce-
dures for the collection and treatment of plant ma-
terials, contaminated samples (by soil, dust, etc.) 
were washed in tap water for a few seconds. The 
lyophilized sample (3 g) was placed in a beaker 
with 200 mL of demineralized water, frozen, and 
then placed in a refrigerator at -20°C. The sample 
was subsequently filtered within a 250-mL balloon, 
lyophilized to remove any water, weighed and re-
dissolved in 10% dimethyl sulfoxide (DMSO) at 
a concentration of 500 mg/mL (stock solution). 
From each stock solution of CWE-Pef and CWE-
Pn, a working solution of 5 mg/mL in McCoy’s 
5A modified medium (sterilized with a sterile filter 
with a 0.22-μm pore size; Millipore, Inc., Billerica, 
MA) was prepared and used for all experimental 
procedures. The maximum dose of mushroom ex-
tract used in the assays was 100 µg/mL containing 
0.002% DMSO. Mushroom extract was added to 
HCT-116 cells 18 hours after seeding.
B. Cell Culture
The human colon carcinoma cell line HCT-116 
was cultured in McCoy’s 5A modified medium 
plus 10% (v/v) dialyzed heat-inactivated fetal bo-
vine serum, 100 U/mL penicillin, and 100 µg/mL 
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streptomycin at 37°C in a humidified atmosphere 
of 95% air and 5% carbon dioxide. Human um-
bilical cord endothelial cells (HUVECs) were ob-
tained from Lonza (Clonetics, Verviers, Belgium) 
and grown in endothelial growth medium accord-
ing to the manufacturer’s indications.
C. Cell Survival Assay
Cell viability was assessed by crystal nuclear stain-
ing.28 In brief, HCT-116 cells and HUVECs were 
seeded in media at respective concentrations of 
2.5 × 104 and 1.5 × 104 cells/cm2 in 96- or 24-well 
plates. After 18 hours, the cells were washed and 
treated for 24 hours with DMSO (used as a control) 
and with different concentrations of either CWE-
Pef or CWE-Pn (10, 20, 50, and 100 μg/mL). At 
the end of the treatment, the culture medium was 
carefully removed and washed twice with com-
plete phosphate-buffered saline; then a solution of 
0.5% crystal violet in 20% methanol was added to 
each well and kept for 10 minutes at room tem-
perature. Finally, the plate was washed, drained, 
and the stain was solubilized by adding a 1:1 (v/V) 
solution of 0.1 M sodium citrate (pH 4.2)/100% 
ethanol at room temperature for 20–30 minutes 
with agitation. The plate was read at 540 nm with 
a microtiter plate reader. The rate of cell growth 
inhibition was calculated, taking into account the 
average results obtained from at least 3 indepen-
dent experiments by calculating the percentage of 
growth in relation to the control with the following 
formula: (optical density of the treated cells/opti-
cal density of the control group) × 100.
D. Apoptosis Assays
HCT-116 cells were treated with 5, 10, 15, and 20 
μg/mL of CWE-Pef or CWE-Pn and with DMSO 
as the control. After 18 hours of culture, cells were 
harvested, collected, washed, and stained with 
acridine orange/ethidium bromide, according to 
the method described by Saydam et al.29 This stain-
ing, combined with fluorescent microscopy, was 
used to distinguish viable from apoptotic cells.30 At 
least 200 cells/field were counted in each experi-
ment. The histograms in figure 3A show, for each 
condition, the percentage of apoptotic cells, which 
was calculated as follows: ([no. of early apoptotic 
cells + no. of late apoptotic cells]/total no. of cells) 
× 100. The values reported in these graphs are the 
average results obtained from at least 3 indepen-
dent experiments.
E. RNA Extraction and Real-Time PCR
HCT-116 cells were treated for 18 hours with dif-
ferent concentrations (10, 20, and 50 μg/mL) of 
either CWE-Pef or CWE-Pn and with DMSO as 
the control. RNA was extracted using the commer-
cially available Illustra RNAspin Mini Isolation 
Kit (GE Healthcare, Little Chalfont, Bucking-
hamshire, UK), according to the manufacturer’s 
instructions. Total RNA was reverse-transcribed 
to complementary DNA using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosys-
tem, Foster City, CA, USA). Real time-PCR was 
performed in 48-well plates using the Step-One 
Real-Time PCR system (Applied Biosystems, Fos-
ter City, CA, USA).
Bax transcription levels were measured by per-
forming a quantitative Sybergreen real-time PCR, 
which was carried out in a total volume of 20 μL 
containing 2× SYBR Green I Master Mix (Applied 
Biosystems), 2 μL complementary DNA, and 300 
nM forward and reverse primers. Cycling condi-
tions were as follows: 95°C for 10 minutes followed 
by 40 cycles of 95°C for 10 seconds and 60°C for 
30 seconds, followed by a dissociation curve anal-
ysis from 60 to 95°C. The primers sequence was 
5′CCTGTGCACCAAGGTGCCGGAACT3′ (for-
ward) 5′CCACCCTGGTCTTGGATCCAGCCC3′ 
(reverse) for Bax; 5′ATGGGGAAGGTGAAG-
GTCG3′ (forward) and 5′GGGTCATTGATGGC 
AACAAT ATC3′ (reverse) for GAPDH. The Bcl-2 
transcription levels were measured by a TaqMan 
real-time quantitative PCR and analyzed as previ-
ously described.31 The following primers obtained 
from Applied Biosystems were used: GAPDH, 
Hs99999905_m1; Bcl-2, Hs00608023_ml. 
Relative changes in gene expression between 
untreated (control) and treated cells were deter-
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mined using the ΔΔCt method. Levels of the target 
transcript were normalized to a GAPDH endoge-
nous control that was constantly expressed in both 
groups (ΔCt). For ΔΔCt values, additional subtrac-
tions were performed between treated and control 
ΔCt values. The final values reported in in Fig. 3C 
were expressed as fold of induction and were the 
average of the results obtained from duplicate ex-
periments.
F. Motility Assays
HCT-116 cells were assayed for their migration 
activity using a modified Boyden chamber meth-
od.32 In brief, polycarbonate filters with an 8-µm 
pore size were coated with 10 µg calf-skin colla-
gen (Calbiochem)/mL acetic acid (0.1 M). Cells (2 
× 106/mL) were suspended in serum-free McCoy’s 
5A modified medium supplemented with 0.1% bo-
vine serum albumin in the presence of increasing 
doses (5, 10, 15, and 20 µg/mL) of either CWE-Pef 
or CWE-Pn (cells with DMSO were used as the 
control) and transferred into the upper wells. Fetal 
bovine serum (10%) in culture medium was used 
as a chemoattractant in the lower chamber. After 
22 hours of incubation at 37°C, cells on the up-
per surface of the membrane were removed with a 
cotton swab and filters were fixed and stained with 
Dif-Quick solution (Medion Diagnostics GmbH, 
Düdingen, Switzerland). The number of migrating 
cells were counted in 10 high-power fields per well 
at 400× magnification. The graphs in Fig. 4 report 
the percentage of migrating cells versus the control 
calculated with the following formula: (no. of mi-
grating treated cells/no. of migrating control cells) 
× 100. Each treatment dose was tested in at least 3 
independent experiments.
G. Cell Aggregation Assay
Cell aggregation assays were performed essential-
ly as described by Zhu et al.33 In brief, a single-cell 
suspension was obtained using a standard tryp-
sinization procedure for cells treated for 18 hours 
with 20 µg/mL of either CWE-Pef or CWE-Pn and 
with DMSO as a control. A total of 2 × 105 cells in 
1 mL of serum-free McCoy’s 5A modified medium 
were placed in polystyrene microtubes and were 
gently shaken for 1 hour at 37°C. At the end, glu-
taraldehyde (at a final concentration of 2% [v/v]) 
was added to stop the aggregation process. Homo-
typic aggregation was evaluated microscopically 
in a hemocytometer by counting only single, non-
aggregating cells. 
The percentage of aggregated cells was calcu-
lated as (1 – Ne/Nc) × 100, where Ne is the number 
of single cells after incubation at 37°C and Nc is 
the number of single cells before incubation (after 
the standard trypsinization procedure). The effect 
of treatment was evaluated by taking into account 
the average results obtained from at least 3 inde-
pendent experiments.
H. Adhesion Assay on the HUVEC 
Monolayer
HUVECs grown to confluence in 24-well plates 
were fixed with glutaraldehyde 0.0125% (Agar 
Scientific Ltd., Stanted, Essex, UK). After fixa-
tion, cells were treated with10 mM ethanolamine 
to block aldehydic groups and washed several 
times before plating the cancer cells. HCT-116 
cells previously treated for 18 hours with increas-
ing doses (1, 5, 10, and 20 µg/mL) of either CWE-
Pef or CWE-Pn and with DMSO as a control were 
detached with trypsin, were resuspended in plain 
medium containing 0.5% bovine serum albumin at 
35 × 104 cells/mL , and for 60 minutes were al-
lowed to attach on the HUVEC monolayer. Each 
well was rinsed twice with phosphate-buffered sa-
line to remove nonadherent cells; the attached cells 
were stained with hematoxylin and eosin. Each 
treatment dose was assayed at least in triplicate; 
5 high-power (400×) fields were counted for each 
well. We reported the percentage of adherent cells 
versus the control calculated with the following 
formula: (no. of adherent treated cells/no. of ad-
herent control cells) × 100 (Fig. 6A). The effect of 
each treatment dose was evaluated by taking into 
account the average results obtained from 3 inde-
pendent experiments.
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I. Western Blot Analysis
Total cell lysates were subjected to sodium do-
decyl sulphate polyacrylamide gel electrophoresis 
followed by Western blotting as previously de-
scribed.31 In brief, HCT-116 cells after 18 hours 
of treatment with different concentrations (10, 20, 
and 50 μg/mL) of either CWE-Pef or CWE-Pn 
or with 0.001% DMSO (used as a control) were 
washed and lysed in lysis buffer (150 mM sodium 
chloride [NaCl], 2 mM TrisHCl [pH 7.5], 1% Tri-
ton, 1 mM phenylmethylsulfonyl fluoride, 1 mM 
EDTA,1 mM EGTA, 1µg/mL leupeptin, 1µg/mL 
aprotinin, 2 mM sodium orthovanadate, 10 mM 
sodium pryophosphate, 100 mM sodium fluoride) 
on ice for 1 hour. The cell lysate was clarified via 
high-speed centrifugation for 15 minutes at 4°C, 
and an aliquot of the supernatant was assayed to 
determine the protein concentration using the 
Bradford method.34 Proteins were separated by 8% 
or 10% sodium dodecyl sulphate polyacrylamide 
gel electrophoresis and transferred to Hybond 
ECL nitrocellulose membrane (GE Healthcare 
Life Sciences). The membrane was incubated in 
block solution (5% nonfat dry milk, 20 mM Tris, 
140 mM NaCl, 0.1% Tween-20), and probed over-
night at room temperature with specific antibodies 
against phosphotyrosine, extracellular signal-reg-
ulated kinase (ERK) 1/2 and phospho-ERK 1/2 
(Cell Signaling Technology, Danvers, MA), ac-
tin,35 and E-cadherin (Cell Signaling Technology). 
After 3 washes with 20 mM Tris, 140 mM NaCl, 
and 0.1% Tween-20, the membrane was incubated 
with horseradish peroxidase-conjugated second-
ary antibodies for 1 hour at room temperature, 
and proteins were detected using the Super Signal 
enhanced chemiluminescence detection system 
(Pierce, Rockford, IL, USA). The results were con-
firmed by at least 3 independent experiments. 
J. Statistical Analysis
Significant differences between treated and un-
treated HCT-116 cells were determined using the 
Student t test, with a significance level set at P < 
0.05.
III. RESULTS AND DISCUSSION
A. Growth Inhibition of HCT-116 Cells by 
CWE-Pef and CWE-Pn
Cancer cells are characterized by their uncontrolled 
growth resulting from the altered function of the 
genes that regulate cell proliferation. Thus, one of 
the main features required to propose a compound 
as an anticancer agent is its ability to inhibit the 
proliferation of cancer cells, thus leading to a re-
duction of the tumor mass.
To perform a preliminary screening of the an-
titumor activity of the CWE-Pef and CWE-Pn, we 
evaluated the proliferation rate of highly invasive 
colon cancer HCT-116 cells by means of a crystal 
violet assay. As shown in Fig. 1A, the treatment of 
cancer cells with increasing concentrations (0–100 
µg/mL) of either CWE-Pef or CWE-Pn for 24 hours 
induced a statistically significant dose-dependent 
decrease of cell viability. Moreover, light micros-
copy also clearly showed that after 24 hours of 
treatment with CWE-Pef the HCT-116 cell mono-
layer was drastically altered in comparison to the 
untreated condition (Fig. 1B), and the same effect 
was observed following treatment with CWE-Pn 
(data not shown). The inhibitory effects on HCT-
116 proliferation was not caused by a nonspecific 
cytotoxic effect of CWE-Pef and CWE-Pn because 
both extracts did not have any significant effect on 
the proliferation of normal cells such as HUVECs 
(Fig. 2). Several data reported in literature widely 
show that natural compounds extracted from nu-
merous mushrooms, including some species of the 
genus Pleurotus, are able to inhibit tumor cell pro-
liferation.5,10,16–19 According to this evidence, our 
results suggest that cold-water extraction allowed 
bioactive compounds that suppress proliferation 
of colon cancer cells without significant effect on 
proliferation of normal cells to be isolated from 
both P. eryngii var. ferulae and P. nebrodensis. 
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B. CWE-Pef and CWE-Pn Induce 
Apoptosis in HCT-116 Cells
An induction of apoptosis is considered a good 
strategy for cancer treatment. Therefore, in the ar-
eas of cancer chemoprevention and chemotherapy, 
many studies have been pursued with the aim of 
identifying mycochemicals of mushroom origin, 
as well as phytochemicals of plant origin, that 
show an ability to induce apoptosis in cancer cells. 
Thus, to determine whether the observed decrease 
in cell number after treatment with CWE-Pef and 
CWE-Pn was due to the induction of apoptosis, we 
performed an acridine orange/ethidium bromide 
double-staining assay. As reported in Fig. 3A, 18 
hours of cell treatment with 20 µg/mL of CWE-Pef 
and CWE-Pn caused a significant increase in the 
percentage of apoptosis compared to the untreated 
cells, and this can be clearly seen in the representa-
tive micrographs in Fig. 3B.
To examine whether the expression of key pro-
apoptotic and antiapoptotic genes could be modu-
lated by CWE-Pef and CWE-Pn treatment, we 
tested messenger RNA (mRNA) expression levels 
of Bcl-2 and Bax in HCT-116 cells after 18 hours 
of treatment with 20 µg/mL of both extracts. Re-
sults indicated that the expression level of Bcl-2 
mRNA was significantly lower in both treatment 
conditions compared to the control, whereas the 
expression of Bax mRNA was significantly and 
markedly increased in cells treated with CWE-
Pef compared to untreated cells, but no significant 
changes were found in HCT-116 cells treated with 
CWE-Pn  (Fig. 3C). However, it is widely reported 
that it is not the increased or decreased expression 
of  Bax or Bcl-2 alone, but rather the ratio of the 2 
molecules that is important in determining a cell’s 
susceptibility to apoptosis. For this reason, the ratio 
of Bax to Bcl-2 at both the protein and mRNA level 
is typically used as an index of apoptosis.36–38 Thus, 
it was interesting to find that, despite the observed 
data at the individual mRNA expression level, 
treatment with both extracts caused a significant 
increase in the Bax:Bcl-2 mRNA ratio (Fig. 3D), 
confirming the ability of CWE-Pef and CWE-Pn 
to promote an apoptotic response in HCT-116 cells 
FIG. 1: The effects of cold-water extracts of Pleurotus eryngii var. ferulae (CWE-Pef) and Pleurotus nebrodensis 
(CWE-Pn) on the proliferation rate and morphology of colon cancer cells. A: HCT-116 cells were treated for 24 hours 
with increasing doses of mushroom extracts. Control cells (CTRL) were maintained in dimethyl sulfoxide 0.002% for 
the same amount of time. Proliferation was assessed after 24 hours, as described in Materials and Methods. Each 
bar represents the mean ± standard deviation of at least 3 independent experiments. **Significant difference (P ≤ 
0.01) in comparison to the control. B: Representative phase-contrast micrographs of HCT116 cells treated for 24 
hours with vehicle (CTRL) and 50 µg/mL CWE-Pef (200× magnification). 
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at the molecular level. Other studies have similarly 
demonstrated that compounds extracted from sev-
eral species of mushrooms, such as Ganoderma 
lucidum (W.Curt.:Fr.) P. Karst., Poria cocos F.A. 
Wolf, Sarcodon scabrosus (Fr.) P. Karst., and Fo-
mitopsis nigrescens (Bres.) Bondartsev & Singer, 
are able to activate apoptosis in cancer cells by in-
ducing an increase of the Bax:Bcl-2 ratio.39–41 Our 
findings provide the first evidence that both CWE-
Pef and CWE-Pn contain compounds that are able 
to induce the apoptosis of colon cancer cells. 
C. Effect of CWE-Pef and CWE-Pn on the 
Migration, Adhesion, and Aggregation of 
Tumor Cells
The reduction in cell-to-cell cohesion and the in-
crease in cell migration are 2 closely interrelated 
cellular processes related to the acquisition of a 
transformed phenotype, and play an important role 
in tumor invasion and metastasis.42 Thus an inves-
tigation of the ability of new natural compounds 
to inhibit the migration of cancer cells and to pro-
mote cell-cell adhesion is considered an aspect of 
particular relevance in order to establish their an-
titumor capabilities. As shown in Fig. 4, 18-hour 
treatment of HCT-116 cells with CWE-Pef and 
CWE-Pn decreased cell motility compared to un-
treated controls, even if with differing efficacy. We 
observed that the CWE-Pef treatment was able to 
inhibit HCT-116 cell motility in a dose-dependent 
manner from 30% (±6%) with 10 µg/mL dose (P 
< 0.05) to 55% (±5%) with a 20 µg/mL dose (P < 
0.01). Otherwise, the CWE-Pn was able to induce 
a significant decrease in cell motility only at the 
dose of 20 µg/mL (about 40% ± 3%; P < 0.05). 
The ability of several mushroom compounds, such 
as those extracted from G. lucidum or Antrodia 
camphorata (M. Zang & C. H. Su) Sheng H. Wu, 
Ryvarden & T.T. Chang, to suppress the migration 
of tumor cells has already been described; an in-
hibitory activity of tumor invasion and metastasis 
FIG. 2: The effects of cold-water extracts of Pleurotus eryngii var. ferulae (CWE-Pef) and Pleurotus nebrodensis 
(CWE-Pn) on the proliferation of human umbilical cord endothelial cells (HUVECs). HCT-116 HUVECs were treated 
for 24 hours with increasing doses of mushroom extracts. Control cells (CTRL) were maintained in dimethyl sulfox-
ide 0.002% for the same amount of time. Proliferation was assessed after 24 hours, as described in Materials and 
Methods. Each bar represents the mean ± standard deviation of at least 3 independent experiments.
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has been reported.43,44
We also assessed whether treatment with 
CWE-Pef and CWE-Pn modulated cell-cell inter-
action by evaluating the ability of HCT-116 cells 
to form cell aggregates. Results, shown in Fig. 5A, 
indicated that the 2 extracts promoted spontaneous 
HCT-116 cell-cell aggregation. Compared to con-
trol conditions, pretreatment for 18 hours with 20 
µg/mL CWE-Pef and CWE-Pn caused an increase 
in aggregated cells of 29% (± 1.2%; P < 0.05) and 
22% (±2.75%; P < 0.01), respectively. 
It is well known that the reduced cell-cell 
adhesion characterizing epithelial cancer cells is 
closely associated with the loss of E-cadherin. In 
FIG. 3: The Effects of cold-water extracts of Pleurotus eryngii var. ferulae (CWE-Pef) and Pleurotus nebrodensis 
(CWE-Pn)on the induction of apoptosis in HCT-116 cells. A: Treatment with CWE-Pef and CWE-Pn for 18 hours 
induced an increase of apoptosis in the HCT-116 cells, as detected by acridine orange/ethidium bromide staining. 
At least 200 cells/field were counted in each experiment. The percentage of apoptotic cells was determined as de-
scribed in Materials and Methods. Each value reported in the graph represents the mean ± standard deviation of at 
least 3 independent experiments. Significant differences in comparison to the control: *P ≤ 0.05; **P ≤ 0.01. B: Rep-
resentative micrographs of HCT-116 cells stained with acridine orange/ethidium bromide after 18 hours of treatment 
with vehicle (CTRL) and 20 µg/mL CWE-Pef. Viable cells are green, whereas apoptotic cells show orange nuclei 
(200× magnification). Modulation of Bcl-2 and Bax messenger RNA expression levels (C) and Bax:Bcl-2 messenger 
RNA ratio (D) in HCT-116 cells treated for 18 hours with 20 µg/mL CWE-Pef and CWE-Pn. GAPDH was used as the 
control gene by following the procedure described in the Materials and Methods. Each value represents the mean 
± standard deviation of duplicate experiments. Significant difference in comparison to the control: *P ≤ 0.05; ** P ≤ 
0.01. FOI, fold of induction (see Materials and Methods).
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light of the positive effect induced by CWE-Pef 
and CWE-Pn on cell aggregation, we wanted to 
verify whether the 2 extracts might modulate the 
expression of E-cadherin. The results obtained by 
Western blot assay supported our hypothesis; it 
was evident that 18 hours of treatment with both 
extracts induced a net increase of E-cadherin ex-
pression in HCT-116 cells (Fig. 5B). This was a re-
ally attractive result because the increase of E-cad-
herin expression is considered a protective event 
that is able to inhibit tumor progression; for this 
reason, therapeutic approaches that aim to increase 
the expression of E-cadherin have been proposed 
for cancer treatment.45 Two recent independent 
works have reported data indicating that 2 triter-
penes extracted from G. lucidum, ganoderic acid T 
and ganodermanontriol, are able to induce cell ag-
gregation and the upregulation of E-cadherin in co-
lon cancer cells.46,47 However, correlations among 
these 2 effects have never been described. In this 
study, we demonstrated that the ability of CWE-
Pef and CWE-Pn to affect the cell-cell adhesion of 
HCT-116 cells is associated with an induction of 
E-cadherin expression. 
Changes in the “adhesive migratory” pheno-
type acquired by tumor cells during the complex 
process of malignant transformation also cause 
cell migration into the host connective tissue, 
FIG. 4: Cold-water extracts of Pleurotus eryngii var. ferulae (CWE-Pef) and Pleurotus nebrodensis (CWE-Pn)inhibit 
the migration of HCT-116 cells. The effect of CWE-Pef and CWE-Pn on the migration of HCT-116 cells was evalu-
ated by using a modified Boyden chamber, as described in the Materials and Methods. The histograms show the 
effects of CWE-Pef (top) and CWE-Pn treatment (bottom) on the percentage of migrating treated cells in comparison 
to the control (Ctrl). Each bar represents the mean ± standard deviation of at least 3 independent experiments. Sig-
nificant difference in comparison to the control: *P ≤ 0.05; ** P ≤ 0.01. 
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intravasation into the cancer-associated vascu-
lature, and extravasation to distant organs. The 
intravasation of cancer cells is a process involv-
ing several steps, including their initial adhesion 
to endothelial cells. Thus, this phase represents 
a crucial starting point for the dissemination of 
cancer cells. Based on this consideration, we per-
formed an adhesion assay to test whether the ad-
hesion of HCT-116 cells to HUVECs was affect-
ed by treatment with CWE-Pef and CWE-Pn. As 
shown in Fig. 6A and B, both extracts were able 
to induce a negative modulation of adhesion of 
cancer cells and HUVECs after 18 hours of pre-
treatment, even if with different modalities. We 
observed that, compared to the control, the maxi-
mum inhibiting effect was already reached by 
CWE-Pef at a dose of 5 µg/mL (about 45% ± 9%; 
P < 0.001), whereas CWE-Pn induced a dose-de-
pendent inhibition of the adhesion of cancer cells 
to the endothelial cells, with an inhibition of 70% 
(±6.8%; P < 0.001) when the maximum dose was 
used (Fig. 6A). The representative phase contrast 
micrographs in Fig. 6B show the decrease in ad-
hesion of HCT-116 cells (dark spherical cells) to 
the HUVEC monolayer (visible as background) 
after 18 hours of pretreatment with 20 µg/mL 
CWE-Pef. Even if there is much data in the litera-
ture that shows angiogenic inhibitory activities 
of several mycochemicals,3 to our knowledge no 
evidence of the effects of mushroom compounds 
in regulating cancer cell–endothelial cell interac-
tion has been reported. 
Taken together, our results indicate that CWE-
Pef and CWE-Pn inhibit HCT-116 cell motility, 
FIG. 5: Cold-water extracts of Pleurotus eryngii var. ferulae (CWE-Pef) and Pleurotus nebrodensis (CWE-Pn) en-
hance cell aggregation and E-cadherin expression. A: After pretreatment of HCT-116 cells for 18 hours with 20 µg/
mL of CWE-Pef and CWE-Pn, the percentage of aggregated cells was determined as described in the Materials and 
Methods. Values reported in each graph are the mean ± standard deviation of at least 3 independent experiments. 
Ctrl, control. B, top: Western blot analysis of E-cadherin in HCT-116 cells treated for 18 hours with the indicated 
dose of CWE-Pef and CWE-Pn (upper panel); Western blot analysis of β-actin was performed to ensure equal load-
ing (bottom panel). B, bottom: Densitogram corresponding to E-cadherin Western blot analysis is shown. The blot 
densities are expressed as folds of control. Data are mean ± standard deviation (n = 3). Significant difference in 
comparison to the control: *P ≤ 0.05; ** P ≤ 0.01.
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preventing interactions with endothelial cells and 
enhancing cell-cell aggregation and thus support-
ing the hypothesis that these extracts can be used 
as new sources of alternative therapeutic agents for 
cancer treatment.
D. Modulation of Cell Signal Pathways by 
CWE-Pef and CWE-Pn
To investigate the biochemical basis of the effects 
of CWE-Pef and CWE-Pn on HCT-116 cells, we 
evaluated the ability of both extracts to modulate 
intracellular signal transduction pathways. There-
fore, we analyzed the global phosphotyrosine 
signature and phosphorylation levels of ERK1/2, 
a key component of the Ras–mitogen-activated 
protein kinase pathway that regulates many criti-
cal cellular pathways involved in cell proliferation, 
apoptosis, migration, and differentiation.48,49
As shown in Fig. 7A, the treatment of HCT-
116 colon cancer cells with CWE-Pef and CWE- 
Pn inhibited tyrosine phosphorylation of different 
proteins compared to DMSO-treated cells (con-
trol). A stronger activity in the modulation of ty-
rosine phosphorylation levels of CWE-Pn com-
pared to CWE-Pef also was observed. Protein 
tyrosine phosphorylation is a dynamic reversible 
posttranslational modification that plays a major 
FIG. 6: Cold-water extracts of Pleurotus eryngii var. ferulae (CWE-Pef) and Pleurotus nebrodensis (CWE-Pn) inhibit 
the adhesion of HCT-116 cells to the human umbilical cord endothelial cell (HUVEC) monolayer. A: After pretreat-
ment for 18 hours with increasing doses of CWE-Pef and CWE-Pn, the adhesion of HCT-116 cells to the HUVEC 
monolayer was determined as described in the Materials and Methods. The 2 histograms show the percentage of 
adherent HCT-116 cells treated with CWE-Pef (top) and CWE-Pn (bottom) in comparison to the control (CTRL). 
Each bar represents the mean ± standard deviation of at least 3 independent experiments. Significant difference in 
comparison to the control: *P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001. B: Representative phase-contrast micrographs show 
the adhesion of HCT116 cells (dark spherical cells) pretreated for 18 hours with dimethyl sulfoxide (Ctrl; top) and 20 
µg/mL CWE-Pef (bottom) on the HUVEC monolayer (visible as background). 
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role in cellular signalling. A balance between pro-
tein tyrosine kinases (PTKs) and protein tyrosine 
phosphatases controls the level of tyrosine phos-
phorylation. The deregulation of PTK and protein 
tyrosine phosphatase activity results in aberrant 
tyrosine phosphorylation, which has been associ-
ated with altered cell function, leading to malig-
nant transformation.49,50 An intense effort has been 
made to design and identify new PTK inhibitors 
for the development of new therapies.51 In light of 
these considerations, it was interesting to observe 
that the 2 mushrooms extract negatively modulat-
ed protein tyrosine phosphorylation. This ability to 
affect PTK signaling may be a newsworthy finding 
that supports the hypothesis of the antitumor activ-
ity of CWE-Pef and CWE- Pn. 
Moreover, our results also showed that the 
phosphorylation of ERK1/2 was markedly inhib-
ited in a dose-dependent manner by CWE-Pef and 
CWE-Pn treatment, with no remarkable changes in 
the total amount of ERK1/2 (Fig. 7B), indicating 
that treatment with both extracts was responsible 
for ERK1/2 inactivation. These data are in accord 
with other previous publications that showed the 
same effects of extracts from several species of 
mushrooms, such as Inonotus obliquus (Pers.:Fr.) 
FIG. 7: The effects of treatment with cold-water extracts of Pleurotus eryngii var. ferulae (CWE-Pef) and Pleurotus 
nebrodensis (CWE-Pn) on intracellular signaling pathways. Whole-cell lysates were prepared from HCT-116 cells 
treated with 10 and 20 µg/mL CWE-Pef and CWE-Pn for 24 hours and subjected to Western blot analysis with anti-
bodies against phosphorylated tyrosine proteins and β-actin to ensure equal loading (A) or with phospho–extracel-
lular signal-regulated kinase (ERK) 1/2 and ERK 1/2 (B), as described in the Materials and Methods. B, bottom: 
Densitogram corresponding to Western blot analysis of phospho-ERK1/2 is shown. The blot densities are expressed 
as folds of control. Data are mean ± standard deviation (n = 3). Significant difference in comparison to the control: 
*P ≤ 0.05; ** P ≤ 0.01.
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Pilát (Chaga mushroom) or A. camphorata.44,52 
ERK1/2 are ubiquitously expressed kinases in-
volved in the Ras-Raf-MEK-ERK signal trans-
duction cascade.53 This pathway is distinctively 
upregulated in a variety of cancers, where it plays 
an important role in altering proliferation, antia-
poptotic behavior, invasiveness, and neovascular-
ization.54 Thus, it is reasonable to suppose that the 
antiproliferative and proapototic effects induced 
by CWE-Pef and CWE- Pn on HCT-116 may be 
related to their inhibitory effect on ERK1/2 phos-
phorylation. 
IV. CONCLUSIONS
Our data suggest that CWE-Pef and CWE- Pn have 
antitumoral properties linked to their ability to spe-
cifically inhibit the proliferation of colon cancer 
cells by inducing apoptosis, as demonstrated by 
the increased Bax:Bcl-2 mRNA ratio, and to their 
capacity to affect cell migration, cell aggregation 
(by modulating E-cadherin expression), and the 
adhesion of tumor cells to endothelial cells. More-
over, we demonstrated that the treatment of HCT-
116 cells with CWE-Pef and CWE-Pn induced 
a negative modulation of intracellular signaling 
pathways specifically associated with the malig-
nant phenotype. In conclusion, our study indicates 
that CWE-Pef and CWE- Pn can be considered 
new sources of efficient therapeutic agents for the 
treatment of cancer. However, further research is 
needed to more thoroughly explore and character-
ize their bioactive components.
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